Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo

Clinical Cancer Research

Volumn 9, Issue 7, 2003, Pages 2826-2836

  Hu, Yan Ping ^a   Cherton Horvat, Gabriele ^e   Dragowska, Visia ^a   Baird, Stephen ^c,d   Korneluk, Robert G ^c,d   Durkin, Jon P ^e   Mayer, Lawrence D ^b   LaCasse, Eric C ^c,e  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b Celator Technologies Inc   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^e Aegera Oncology Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CASPASE 3; DNA FRAGMENT; DOXORUBICIN; ETOPOSIDE; INHIBITOR OF APOPTOSIS PROTEIN; MESSENGER RNA; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ENZYME DEGRADATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASES; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME INHIBITORS; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, SCID; MICROSCOPY, CONFOCAL; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES, ANTISENSE; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 0037478904     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Bunn, P. A. J., Vokes, E. E., Langer, C. J., and Schelller, J. H. An update on North American randomized studies in non-small cell lung cancer. Semin. Oncol., 25: 2-10, 1998.
2. Webb, A., Cunningham, D., Cotter, F., Clarke, P. A., Di Stefano, F., Ross, P., Corbo, M., and Dziewanowska, Z. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet, 349: 1137-1141, 1997.
3. Banerjee, D. Technology evaluation: G-3139. Curr. Opin. Mol. Ther., 1: 404-408, 1999.
4. Ziegler, A., Simoes-Wuest, A. P., and Zangemeister-Wittke, U. Optimizing efficacy of antisense oligonucleotides targeting inhibitors of apoptosis. Methods Enzymol., 314: 477-490, 2000.
5. Evan, G., and Littlewood, T. A. A matter of life and cell death. Science (Wash. DC), 281: 1317-1322, 1998.
6. Evan, G. I., and Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. Nature (Lond.), 411: 342-348, 2001.
7. Deveraux, Q. L., Takahashi, R., Salvesen, G. S., and Reed, J. C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature (Lond.), 388: 300-304, 1997.
8. Deveraux, Q. L., Roy, N., Stennicke, H. R., Van Arsdale, T., Zhou, Q., Srinivasula, S. M., Alnemri, E. S., Salvesen, G. S., and Reed, J. C. IAPs block apoptotic events induced by caspase-8 and cytochrome c by distinct inhibition of distinct caspases. EMBO J. 17: 2215-2223, 1998.
9. Roy, N., Deveraux, Q. L., Takahashi, R., Salvesen, G. S., and Reed, J. C. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 16: 6914-6925, 1997.
10. Tamm, I., Wang, Y., Sausville, E., Scudiero, D. A., Vigna, N., Oltersdorf, T., and Reed, J. C. IAP-family protein Survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Dax, caspases and anticancer drugs. Cancer Res., 58: 5315-5320, 1998.
11. Datta, R., Oki, E., Endo, K., Biedermann, V., Ren, J., and Kufe D. XIAP regulates DNA damage-induced apoptosis downstream of caspase-9 cleavage. J. Biol. Chem., 275: 31733-31738, 2000.
12. Takahashi, R., Deveraux, Q., Tamm, I., Welsh, K., Assa-Munt, N., Salvesen, G. S., and Reed, J. C. A single BIR domain of XIAP sufficient for inhibiting caspases. J. Biol. Chem., 273: 7787-7790, 1998.
13. Deveraux, Q. L., Leo, E., Stennicke, H. R., Welsh, K., Salvesen, G. S., and Reed, J. C. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J., 18: 5242-5251, 1999.
14. LaCasse, E. C., Baird, S., Korneluk, R. G., and MacKenzie, A. E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene, 17: 3247-3259, 1998.
15. Holcik, M., Yeh, C., Korneluk, R. G., and Chow, T. Translational up-regulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene, 19: 4174-4177, 2000.
16. Yang, Y., Fang, S., Jensen, J. P., Weissman, A. M., and Ashwell, J. D. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science (Wash. DC), 288: 874-877, 2000.
17. Suzuki, Y., Nakabayashi, Y., and Takahashi, R. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc. Natl. Acad. Sci. USA, 98: 8662-8667, 2001.
18. Cavalli F., Isaacson, P. G., Gascoyne, R. D., and Zucca, E. MALT lymphomas. Hematology, (Am. Soc. Hematol. Educ. Program) 241-258, 2001.
19. Tamm, I., Kornblau, S. M., Segall, H., Krajewski, S., Welsh, K., Kitada, S., Scudiero, D. A., Tudor, G., Qui, Y. H., Monks, A., Andreeff, M., and Reed, J. C. Expression and prognostic significance of IAPfamily genes in human cancer and myeloid leukemias. Clin. Cancer Res., 6: 1796-1803, 2000.
20. Fong, W. G., Liston, P., Rajcan-Separovic, E., St-Jean, M., Craig, C., and Korneluk, R. G. Expression and genetic analysis of XIAPassociated factor 1 (XAF1) in cancer cell lines. Genomics, 70: 113-122, 2000.
21. Lope de Menezes, D. E., Hudon, N., McIntosh, N., and Mayer, L. D. Molecular and pharmacokinetic properties associated with the therapeutics of Bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin. Cancer Res., 6: 2891-2902, 2000.
22. Stein, C. A., and Cheng, Y. C. Antisense oligonucleotides as therapeutics agents is the bullet really magical? Science (Wash. DC), 261: 1004-1012, 1993.
23. Ho, P. T., and Parkinson, D. R. Antisense oligonucleotides as therapeutics for malignant disease. Semin. Oncol., 24: 187-202, 1997.
24. Wintersberger, U. Ribonucleases H retroviral and cellular origin. Pharmacol. Ther., 48: 259-280, 1990.
25. Jansen, B., Schlagbauer-Wadl, H., Brown, B. D., Bryan, R. N., van Elsas, A., Muller, M., Wolff, K., Eichker, H., and Pehamberger, H. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med., 4: 232-234, 1998.
26. Klasa, R. J., Bally, M. B., Ng, R., Goldie, J. H., Gascoyne, R., and Wong, F. M. P. Eradication of human non-Hodgkin's lymphoma in SCID mice by Bcl-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin. Cancer Res., 6: 2492-2500, 2000.
27. Miyake, H., Tolcher, A., and Gleave, M. E. Antisense Bcl-2 oligonucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res., 59: 4030-4034, 1999.
28. Silke, J., Ekert, P. G., Day, C. L., Hawkins, C. J., Baca, M., Chew, J., Pakusch, M., Verhagen, A. M., and Vaux, D. L. Direct inhibition of caspase 3 is dispensable for the anti-apoptotic activity of XIAP. EMBO J., 20: 3114-3123, 2001.
29. Bratton, S. B., Walker, G., Srinivasula, S. M., Sun, X. M., Butterworth, M., Alnemri, E. S., and Cohen, G. M. Recruitment, activation and retention of caspases-9 and-3 by Apaf-1 apoptosome and associated XIAP complexes. EMBO J., 20: 998-1009, 2001.
30. Janicke, R., Sprengart, M. L., Wati, M. R., and Porter, A. G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem., 273: 9357-9360, 1998.
31. Sasaki, H., Sheng, Y. L., Kotsuji, F., and Tsang, B. K. Downregulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res., 60: 5659-5666, 2000.
32. Lin, H., Chen, C., and Chen, D. M. Resistance of bone marrowderived macrophages to apoptosis is associated with the expression of X-linked inhibitor of apoptosis protein in primary cultures of bone marrow cells. Biochem. J., 353: 299-306, 2001.
33. Weiner, G. J., Liu, H. M., Wooldridge, J. E., Dahle, C. E., and Krieg, A. M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA, 94: 10833-10837, 1994.
34. Ballas, Z. K., Rasmussen, W. L., and Krieg, A. M. Induction of NK activity in murine and human cells by CpG motif in oligodeoxynucleotides and bacterial DNA. J. Immunol., 157: 1840-1845, 1996.
35. Duckett, C. S., Nava, V. E., Gedrich, R. W., Clem, R. J., Van Dongen, J. L., Gilfillan, M. C., Shiels, H., Hadwick, J. M. and Thompson, C. B. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. EMBO J., 15: 2685-2694, 1996.
36. Farahani, R., Fong, W. G., Korneluk, R. G., and MacKenzie, A. E. Genomic organization and primary characterization of miap-3: the murine homologue of human X-linked IAP. Genomics, 42: 514-518, 1997.
37. Liston, P., Roy, N., Tamai, K., Lefebvre, C., Baird, S., ChertonHorvat, G., Farahani, R., McLean, M., Ikeda, J. E., MacKenzie, A., and Korneluk, R. G. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature (Lond.), 379: 349-353, 1996.
38. Harlin, H., Reffey, S. B., Duckett, C. S., Linsten, T., and Thompson, C. B. Characterization of XIAP-deficient mice. Mol. Cell. Biol., 21: 3604-3608, 2001.
39. Johnson, J. L., Decker, S., Zaharevitz, D., Rubinstein, L. V., Venditti, J. M., Schepartz, S., Kalyandrug, S., Christian, M., Arbuck, S., Hollingshead, M., and Sausville, E. A. Relationship between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer, 84: 1424-1431, 2001.
40. Chou, T. C., and Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22: 27-55, 1984.